BR0307712A - Composto, composição e uso dos mesmos no tratamento de infecções por flaviviridae e proliferação celular anormal - Google Patents

Composto, composição e uso dos mesmos no tratamento de infecções por flaviviridae e proliferação celular anormal

Info

Publication number
BR0307712A
BR0307712A BR0307712-8A BR0307712A BR0307712A BR 0307712 A BR0307712 A BR 0307712A BR 0307712 A BR0307712 A BR 0307712A BR 0307712 A BR0307712 A BR 0307712A
Authority
BR
Brazil
Prior art keywords
composition
cell proliferation
abnormal cell
compound
treatment
Prior art date
Application number
BR0307712-8A
Other languages
English (en)
Inventor
Lieven Stuyver
Junxing Shi
Kyoichi A Watanabe
Original Assignee
Pharmasset Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasset Ltd filed Critical Pharmasset Ltd
Publication of BR0307712A publication Critical patent/BR0307712A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Abstract

"COMPOSTO, COMPOSIçãO E USO DOS MESMOS NO TRATAMENTO DE INFECçõES POR FLAVIVIRIDAE E PROLIFERAçãO CELULAR ANORMAL". A invenção é um composto, composição, uso e um método de tratamento de infecções por Plaviviridae (Hepacivírus, Flavivírus, Pestivírus), incluindo BVDV e HCV ou proliferação celular anormal, incluindo tumores malignos, em um hospedeiro, incluindo animais, e especialmente seres humanos, usando-se um <225>-D ou <225>-L nucleosídeo de fórmula geral (1) - (XX), ou seu sal farmaceuticamente aceitável ou pró-droga do mesmo.
BR0307712-8A 2002-02-14 2003-02-13 Composto, composição e uso dos mesmos no tratamento de infecções por flaviviridae e proliferação celular anormal BR0307712A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35741102P 2002-02-14 2002-02-14
US35814002P 2002-02-20 2002-02-20
PCT/US2003/004379 WO2003068162A2 (en) 2002-02-14 2003-02-13 Modified fluorinated nucleoside analogues

Publications (1)

Publication Number Publication Date
BR0307712A true BR0307712A (pt) 2005-05-24

Family

ID=27737594

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307712-8A BR0307712A (pt) 2002-02-14 2003-02-13 Composto, composição e uso dos mesmos no tratamento de infecções por flaviviridae e proliferação celular anormal

Country Status (12)

Country Link
US (2) US20040002476A1 (pt)
EP (2) EP1480982A4 (pt)
JP (2) JP2005522443A (pt)
KR (2) KR20040094692A (pt)
CN (2) CN1646534A (pt)
AU (2) AU2003217402A1 (pt)
BR (1) BR0307712A (pt)
CA (2) CA2476279A1 (pt)
MX (2) MXPA04007876A (pt)
NZ (1) NZ534811A (pt)
WO (2) WO2003068162A2 (pt)
ZA (1) ZA200406858B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100003313A (ko) 2000-04-13 2010-01-07 파마셋 인코포레이티드 간염 바이러스 감염 치료를 위한 3'- 또는 2'-하이드록시메틸 치환된 뉴클레오시드 유도체
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CN1315862C (zh) 2000-05-26 2007-05-16 艾登尼科斯（开曼）有限公司 处理黄病毒和瘟病毒的方法和组合物
JP2005504087A (ja) * 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド ４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
US20040197321A1 (en) * 2002-03-19 2004-10-07 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20030180279A1 (en) * 2002-03-19 2003-09-25 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
CN1678326A (zh) * 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
MXPA05001298A (es) 2002-08-01 2005-11-04 Pharmasset Inc Compuestos con el sistema biciclo[4.2.1] nonano para el tratamiento de infecciones por flaviviridae.
US20040067877A1 (en) 2002-08-01 2004-04-08 Schinazi Raymond F. 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
CA2506129C (en) * 2002-11-15 2015-02-17 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
EP2319853B1 (en) * 2002-12-12 2014-03-12 IDENIX Pharmaceuticals, Inc. Process for the production of 2'-branched nucleosides
KR20050110611A (ko) * 2002-12-23 2005-11-23 이데닉스 (케이만) 리미티드 3'-뉴클레오사이드 프로드럭의 생산 방법
MXPA05010419A (es) * 2003-03-28 2006-05-31 Pharmasset Inc Compuestos para el tratamiento de infecciones por flaviviridae.
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
ES2351603T3 (es) * 2003-07-25 2011-02-08 Idenix Pharmaceuticals, Inc. Análogos de nucleósidos de purina para el tratamiento de enfermedades causadas por flaviridae incluyendo hepatitis c.
WO2005018330A1 (en) * 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
CA2571675A1 (en) * 2004-06-23 2006-01-05 Idenix (Cayman) Limited 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
US7524831B2 (en) 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
BRPI0613796A2 (pt) 2005-06-07 2011-02-15 Univ Yale composicões farmacêuticas e seus usos, e métodos de tratamento de cáncer e outras condições ou estados patológicos, por meio do uso de clevudina (lfmau) e telbivudina (ldt)
EP1968595A4 (en) * 2005-12-02 2014-05-21 Univ Yale METHOD OF TREATING CANCER AND OTHER CONDITIONS OR SICKNESS CONDITIONS USING L-CYTOSIN NUCLEOSIDE ANALOGS
CA2634749C (en) * 2005-12-23 2014-08-19 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
JP5734655B2 (ja) * 2007-09-17 2015-06-17 アッヴィ・バハマズ・リミテッド 抗感染症ピリミジンおよびその使用
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
US20100021505A1 (en) * 2008-07-28 2010-01-28 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
JPWO2010027005A1 (ja) 2008-09-05 2012-02-02 壽製薬株式会社 置換アミン誘導体及びこれを有効成分とする医薬組成物
AR084393A1 (es) * 2010-06-10 2013-05-15 Gilead Sciences Inc Metodos para tratar el virus de la hepatitis c, composicion, uso, combinacion, kit y uno o mas compuestos anti vhc
EP2912050A4 (en) 2012-10-29 2016-09-28 Cocrystal Pharma Inc NUCLEOTIDES PYRIMIDINES AND THEIR MONOPHOSPHATE PRODRUGS FOR THE TREATMENT OF VIRAL INFECTIONS AND CANCER
DK3150616T3 (en) 2012-11-16 2017-06-06 Univ College Cardiff Consultants Ltd MIXTURE OF RP / SP GEMCITABIN- [PHENYL- (BENZYLOXY-L-ALANINYL)] - PHOSPHAT
BR112015025716A2 (pt) 2013-04-12 2017-07-18 Achillion Pharmaceuticals Inc pró-fármacos de nucleosídeo submetidos a deutério úteis para o tratamento de hcv
EA037248B1 (ru) 2015-10-05 2021-02-26 НУКАНА ПиЭлСи Применение гемцитабин[фенил-бензокси-l-аланинил]фосфата в комбинации с карбоплатином
BR112019022470A2 (pt) * 2017-04-26 2020-05-12 I. Kalman Thomas Composto, composição, e, método para tratamento de um indivíduo com câncer.
JP2020125245A (ja) * 2019-02-01 2020-08-20 ダイキン工業株式会社 抗ｃ型肝炎ウイルス剤

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ATE92499T1 (de) * 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
HU204843B (en) * 1988-09-27 1992-02-28 Merrell Dow Pharma Process for producing 2'-halogen-methylidene adenosine derivatives and pharmaceutical compositions comprising same
CA2002648C (en) * 1988-11-15 2000-02-29 James R. Mccarthy 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives
US5616702A (en) * 1988-11-15 1997-04-01 Merrell Pharmaceuticals Inc. 2-'-ethenylidene cytidine, uridine and guanosine derivatives
US5705363A (en) * 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
TW224053B (pt) * 1991-09-13 1994-05-21 Paul B Chretien
DK0664708T3 (da) * 1992-04-10 1998-11-02 Merrell Pharma Inc Metode til behandling af cancer ved kombinationsbehandling med 2'-halogenmethylidenderivater og et S-fase- eller M-fase-spe
NZ251886A (en) * 1992-05-12 1996-02-27 Merrell Dow Pharma Ribonucleotide reductase inhibitors and their production
YU43193A (sh) * 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
ATE181557T1 (de) * 1993-02-24 1999-07-15 Jui H Wang Zusammensetzungen und methoden zur anwendung von reaktiven antiviralen polymeren
EP0773029A4 (en) * 1993-07-19 1997-09-03 Tokyo Tanabe Co HEPATITIS C VIRUS PROLIFERATION INHIBITOR
DE4432623A1 (de) * 1994-09-14 1996-03-21 Huels Chemische Werke Ag Verfahren zur Bleichung von wäßrigen Tensidlösungen
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
GB9601680D0 (en) * 1996-01-27 1996-03-27 Pfizer Ltd Therapeutic agents
US5980884A (en) * 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
US5830905A (en) * 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5891874A (en) * 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
US5922757A (en) * 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
JP3963488B2 (ja) * 1997-06-30 2007-08-22 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツンク ウント コンパニー コマンディゲゼルシャフト アウフ アクチェン １−アミノ−アルキルシクロヘキサンｎｍｄａ受容体拮抗薬
DE69933860T2 (de) * 1998-02-25 2007-05-31 Emory University 2'-fluoronukleoside
GB9806815D0 (en) * 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
WO2000021565A1 (en) * 1998-10-13 2000-04-20 Du Pont Pharmaceuticals Company Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent
JP2003523978A (ja) * 2000-02-18 2003-08-12 シャイアー・バイオケム・インコーポレイテッド ヌクレオシドアナログを用いるｆｌａｖｉｖｉｒｕｓ感染の処置もしくは予防するための方法
YU7503A (sh) * 2000-08-02 2006-03-03 Ortho-Mcneil Pharmaceutical Inc. Anti-virusna i anti-tumorna hemoterapija poboljšana davanjem eritropoetina
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
EP1373288B1 (en) * 2001-03-30 2005-06-29 Gilead Sciences, Inc. Process for the preparation of 2'-halo-beta-l-arabinofuranosyl nucleosides

Also Published As

Publication number Publication date
EP1480982A2 (en) 2004-12-01
AU2003217402A1 (en) 2003-09-04
EP1482943A2 (en) 2004-12-08
US20030225029A1 (en) 2003-12-04
US20040002476A1 (en) 2004-01-01
NZ534811A (en) 2007-07-27
EP1480982A4 (en) 2007-08-01
MXPA04007878A (es) 2005-06-20
JP2006505490A (ja) 2006-02-16
CN1646534A (zh) 2005-07-27
CN1646129A (zh) 2005-07-27
CA2476279A1 (en) 2003-08-21
MXPA04007876A (es) 2005-06-20
ZA200406858B (en) 2005-09-28
CA2476282A1 (en) 2003-08-21
AU2003217414A1 (en) 2003-09-04
WO2003068162A2 (en) 2003-08-21
KR20040094692A (ko) 2004-11-10
JP2005522443A (ja) 2005-07-28
WO2003068162A3 (en) 2004-03-11
AU2003217414A8 (en) 2003-09-04
WO2003068164A3 (en) 2004-03-11
KR20040091052A (ko) 2004-10-27
WO2003068164A2 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
BR0307712A (pt) Composto, composição e uso dos mesmos no tratamento de infecções por flaviviridae e proliferação celular anormal
BR0116221A (pt) Agentes antivirais para tratamento de infecções por flaviviridae
MXPA05001298A (es) Compuestos con el sistema biciclo[4.2.1] nonano para el tratamiento de infecciones por flaviviridae.
HK1148470A1 (en) Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
AP1727A (en) Methods and compositions for treating flaviviruses and pestiviruses.
BRPI0410846A (pt) compostos, composições e usos para o tratamento de uma infecção por flaviviridae
BRPI0515896A (pt) composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus
AU3595500A (en) Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
TW200500375A (en) Modified 2&#39; and 3&#39;-nucleoside prodrugs for treating flaviviridae
BR0212924A (pt) Inibidores de glicogênio sintase quinase-3 (gsk-3) para o tratamento de glaucoma
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
RS113904A (en) 2&#39;-c-methyl-3&#39;-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
AP1782A (en) Use of compounds ?-D or ?-L nucleoside for treating hepatitis C virus.
MY151199A (en) Substituted diphenyl heterocycles useful for treating hcv infection
EA200400536A1 (ru) Макролиды
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
EA200200922A1 (ru) Композиция, включающая камптотецин и производное пиримидина, для лечения рака
WO2001008672A3 (en) Glucamine compounds for treating hepatitis virus infections
TR200103418T2 (tr) Melatoninin tedavi edici kullanımı.
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
ATE366720T1 (de) Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
UY26735A1 (es) Métodos y composiciones para tratar flavivirus y pestivirus

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A(S) 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.